CDA | Evidence Driven
CDA | Evidence Driven

Eslicarbazepine acetate

Details

Files
Generic Name:
Eslicarbazepine acetate
Project Status:
Complete
Therapeutic Area:
Epilepsy, partial-onset seizures
Manufacturer:
Sunovion Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Aptiom
Project Line:
Reimbursement Review
Project Number:
SR0391-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Epilepsy, partial-onset seizures
Recommendation Type:
List with criteria/condition
Final Recommendation:

Files

Submission Status Report View PDF
Recommendation and Reasons View PDF
Clinical Report View PDF
Pharmacoeconomic Report View PDF
Patient Group Input Submissions View PDF
Last Updated : August 15, 2014